Brandon White

Practice Areas

Litigation

Intellectual Property Law

ITC Litigation

Patent Litigation

Post-Grant Proceedings

Inter Partes Review (IPR)

Covered Business Method Review (CBM)

Reexaminations & Reissues

Trademark, Copyright, Internet & Advertising

Biotechnology & Pharmaceutical

Career

Brandon White’s practice focuses on pharmaceutical patent and regulatory litigation under the Hatch-Waxman Act and USPTO post-grant proceedings. He represents some of the largest generic pharmaceutical companies in complex and legally significant pharmaceutical patent cases.

Brandon recently first-chaired a trial victory in a case challenging a patent on Zytiga® and argued the successful corresponding inter partes review (IPR). Brandon secured a non-institution decision on four IPRs for Dymista® and prevailed at the motion-to-dismiss phase in a contract dispute on the same drug. He also secured a summary judgment win in a regulatory action related to the definition of “biological product.” Brandon and his team also recently invalidated patents alleged to cover Copaxone® at trial and in three separate IPR proceedings, all of which were affirmed on appeal. He has handle cases relating to liraglutide, dimethyl fumarate, lenalidomide, glatiramer acetate, rasagiline, esomeprazole, rosuvastatin, cyclosporine, fingolimod and levofloxacin, Dymista®, and Astepro®, among many others.

In another recent noteworthy win, Brandon was part of the team that defended against an attempt to use tribal sovereign immunity to shield patents from IPR review. The firm’s work on that matter was awarded the LMG Life Sciences “Impact Case of the Year Award.”